biostudies-literatureLittle MPIntramural NIH HHS451-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC3440544biostudies-literatureUnknown85(2)<h4>Purpose</h4>To assess the shape of the dose response for various cancer endpoints and modifiers by age and time.<h4>Methods and materials</h4>Reanalysis of the US peptic ulcer data testing for heterogeneity of radiogenic risk by cancer endpoint (stomach, pancreas, lung, leukemia, all other).<h4>Results</h4>There are statistically significant (P<.05) excess risks for all cancer and for lung cancer and borderline statistically significant risks for stomach cancer (P=.07), and leukemia (P=.06), with excess relative risks Gy(-1) of 0.024 (95% confidence interval [CI] 0.011, 0.039), 0.559 (95% CI 0.221, 1.021), 0.042 (95% CI -0.002, 0.119), and 1.087 (95% CI -0.018, 4.925), respectively. There is statistically significant (P=.007) excess risk of pancreatic cancer when adjusted for dose-respInternational journal of radiation oncology, biology, physicsA reanalysis of curvature in the dose response for cancer and modifications by age at exposure following radiation therapy for benign disease.PMC3440544Z99 CA999999Smith SAKleinerman RAStovall MLittle MPfalseA reanalysis of curvature in the dose response for cancer and modifications by age at exposure following radiation therapy for benign disease.<h4>Purpose</h4>To assess the shape of the dose response for various cancer endpoints and modifiers by age and time.<h4>Methods and materials</h4>Reanalysis of the US peptic ulcer data testing for heterogeneity of radiogenic risk by cancer endpoint (stomach, pancreas, lung, leukemia, all other).<h4>Results</h4>There are statistically significant (P<.05) excess risks for all cancer and for lung cancer and borderline statistically significant risks for stomach cancer (P=.07), and leukemia (P=.06), with excess relative risks Gy(-1) of 0.024 (95% confidence interval [CI] 0.011, 0.039), 0.559 (95% CI 0.221, 1.021), 0.042 (95% CI -0.002, 0.119), and 1.087 (95% CI -0.018, 4.925), respectively. There is statistically significant (P=.007) excess risk of pancreatic cancer when adjusted for dose-resp2013-01-01T00:00:00Z2013 Feb2025-04-04T08:09:03.096Z2019-03-26T23:05:12ZS-EPMC34405442268281010.1016/j.ijrobp.2012.04.029